Accepted Manuscript

"Uterine fibroid: from pathogenesis to clinical management"

Prof. Felice Petraglia, Editor-in-Chief of Human Reproduction Update, Professor of Obstetrics and Gynecology

PII: S1521-6934(16)00003-1

DOI: 10.1016/j.bpobgyn.2016.01.002

Reference: YBEOG 1587

To appear in: Best Practice & Research Clinical Obstetrics & Gynaecology

Received Date: 12 January 2016

Accepted Date: 12 January 2016

Please cite this article as: Petraglia F, "Uterine fibroid: from pathogenesis to clinical management", *Best Practice & Research Clinical Obstetrics & Gynaecology* (2016), doi: 10.1016/j.bpobgyn.2016.01.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Preface

"Uterine fibroid: from pathogenesis to clinical management"

Uterine fibroid or leiomyoma is the most common benign gynecological tumor in premenopausal women (15-25%). Even though it is a well known clinical problem and deeply studied, the last decade was characterized by an incredible amount of novel information on the pathogenesis and by a concomitant increase of therapeutical proposals. For this reason the present issue aims to update the various biological and medical aspects related to uterine fibroid.

The hyphotesis of stem cell generating leiomyoma, the role of epigenetic/cytegenetic anomalies/mutations and the over expression of micro RNA are hot topic in exploring the increased cell proliferation and the excessive formation of extracellular matrix. The role of sex steroid hormones (estrogens, progesterone) still remains a key point in the pathogenesis of uterine leiomyoma, and, particularly, ERs and PRs have a role in development and maintenance of tumor growth, and new receptor modulators are attractive for the medical treatment of uterine fibroid. Estrogens and progesterone act via a large group of growth factors (in particular, the family of TGFB), which, activating multiple signaling pathways, regulate major cellular processes,

Download English Version:

https://daneshyari.com/en/article/6169075

Download Persian Version:

https://daneshyari.com/article/6169075

<u>Daneshyari.com</u>